Online citations, reference lists, and bibliographies.
← Back to Search

Clinical And Metabolic Effects Of Different Doses Of Prostaglandin E1 In Man. Prostaglandin And Related Factors.

L. Carlson, L. G. Ekelund, L. Orö
Published 1968 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
(PGE1) Prostaglandin E1 was infused intravenously into 8 healthy male subjects. The dose was successively increased to the maximal tolerable dose and varied from 0.032-0.58 mcg/kg/minute. When the lower doses were given there were either no clinical effects or only a flushing of the face. However when the dose was increased the flushing generally became more intensive and extended to other parts of the body mainly the arms and hands. In some of the subjects the flushing diminished and even changed to pallor with the highest doses of PGE1. All subjects complained of headache which usually became severe. In 1 subject the headache was unilateral and was accompanied by visual symptoms. All subjects developed cramps in the upper abdomen which generally become so severe that the administration of PGE1 had to be stopped. Several of the subjects also felt sore in other parts of the body such as the back and legs. The various symptoms disappeared within 15-30 minutes after the end of the infusion. The arterial levels of (FFA) free fatty acids in blood plasma increased in all subjects. In several cases the rise was discontinuous and in 2 of them a decrease in FFA level was seen. FFA response to PGE1 was neither related to administered doses nor to clinical effects. Turnover rate studies with labelled palmitic acid showed that the plasma FFA changes were mainly caused by variations in the rate of mobilizaton of FFA into the blood. The plasma levels of glycerol showed the same type of response to PGE1 as the FFA levels. No significant changes in blood glucose were seen in the subjects who were fasting. The 1 subject who had breakfast showed a rapid rise int he blood glucose concentration. (Authors modified)
This paper references
Titration of free fatty acids of plasma: a study of current methods and a new modification.
D. Trout (1960)
10.1016/0009-8981(64)90171-8
DETERMINATION OF HEPARIN-INDUCED LIPOPROTEIN LIPASE ACTIVITY IN HUMAN PLASMA.
J. Boberg (1964)
10.1172/JCI104791
Turnover rate and oxidation of free fatty acids of blood plasma in man during exercise: studies during continuous infusion of palmitate-1-C14.
R. Havel (1963)
10.1016/0024-3205(67)90155-5
Metabolic and cardio-vascular effects of serotonin.
L. Carlson (1967)
10.1111/j.1749-6632.1965.tb34784.x
INHIBITION OF THE MOBILIZATION OF FREE FATTY ACIDS FROM ADIPOSE TISSUE *
L. A. Carlson (1965)
10.1111/J.1748-1716.1964.TB02880.X
EFFECT OF PROSTAGLANDINS ON CATECHOLAMINE INDUCED CHANGES IN THE FREE FATTY ACIDS OF PLASMA AND IN BLOOD PRESSURE IN THE DOG. PROSTAGLANDIN AND RELATED FACTORS 22.
S. Bergstroem (1964)
10.1111/J.1748-1716.1966.TB03295.X
Effect of prostaglandin E on plasma free fatty acids and blood glucose in the dog. Prostaglandin and related factors 51.
S. Bergström (1966)
10.3891/ACTA.CHEM.SCAND.14-1693
The isolation of prostaglandin F from sheep prostate glands.
S. Bergstroem (1960)
10.1111/J.1748-1716.1965.TB04187.X
Cardiovascular and metabolic response to infusions of prostaglandin E1 and to simultaneous infusions of noradrenaline and prostaglandin E1 in man. Prostaglandin and related factors 35.
S. Bergström (1965)
10.1172/JCI105030
EFFECTS OF THE PROSTAGLANDINS ON HORMONE-INDUCED MOBILIZATION OF FREE FATTY ACIDS.
D. Steinberg (1964)
10.1152/JAPPL.1964.19.4.613
TURNOVER RATE AND OXIDATION OF DIFFERENT FREE FATTY ACIDS IN MAN DURING EXERCISE.
R. Havel (1964)
10.1111/J.1748-1716.1966.TB03231.X
The Biological Activities of Three Metabolites of Prostaglandin E1
E. Änggård (1966)
10.1111/J.1748-1716.1965.TB04059.X
INHIBITORY ACTION OF PROSTAGLANDIN E ON THE MOBILIZATION OF FREE FATTY ACIDS AND GLYCEROL FROM HUMAN ADIPOSE TISSUE IN VITRO. PROSTAGLANDIN AND RELATED FACTORS.
S. Bergstroem (1965)
10.1111/J.1748-1716.1965.TB04086.X
CONCENTRATION AND TURNOVER OF THE FREE FATTY ACIDS OF PLASMA AND CONCENTRATION OF BLOOD GLUCOSE DURING EXERCISE IN HORSES.
L. Carlson (1965)
10.1172/JCI103259
A relation between non-esterified fatty acids in plasma and the metabolism of glucose.
V. Dole (1956)
10.1111/J.1748-1716.1965.TB04289.X
Influence of the nutritional state on the inhibition of lipolysis in adipose tissue by Prostaglandin E1 and nicotinic acid. Prostaglandin and related factors 46.
S. Bergström (1965)
10.1111/j.1749-6632.1967.tb41255.x
THE EFFECTS OF THE CATECHOLAMINES, ADRENERGIC BLOCKING AGENTS, PROSTAGLANDIN E1, AND INSULIN ON CYCLIC AMP LEVELS IN THE RAT EPIDIDYMAL FAT PAD IN VITRO *
R. W. Butcher (1967)
10.1111/J.1748-1716.1959.TB01686.X
Observations on the effects of infusion of prostaglandin E in man.
S. Bergstrom (1959)
10.1016/0009-8981(96)83704-1
An improved glucose-oxidase method for determining blood, C.S.F. and urine glucose levels. 1959.
V. Marks (1996)
10.1016/0006-2952(63)90053-4
Effects of prostaglandin E opposing those of catecholamines on blood pressure and on triglyceride breakdown in adipose tissue.
D. Steinberg (1963)
10.1152/AJPLEGACY.1961.201.3.535
Plasma free fatty acid turnover during insulin-induced hypoglycemia.
D. Armstrong (1961)
10.1111/J.1748-1716.1966.TB03299.X
Effect of different doses of prostaglandin E on free fatty acids of plasma, blood glucose and heart rate in the nonanesthetized dog. Prostaglandin and related factors 53.
S. Bergström (1966)
10.1210/JCEM-20-10-1333
METABOLIC AND CARDIOVASCULAR CHANGES DURING A STATE OF ACUTE CENTRAL NERVOUS SYSTEM AROUSAL
M. Bogdonoff (1960)



This paper is referenced by
Menstrual migraine in the general population – prevalence, clinical characteristics and classification
K. G. Vetvik (2015)
10.1046/j.1468-2982.1985.0502107.x
Acute Migraine Attack Therapy: Comparison of Naproxen Sodium and an Ergotamine Tartrate Compound
A. Pradalier (1985)
10.1007/BF02552673
Prostaglandin E1 for alleviating symptoms of ergot intoxication: A case report
J. Levy (2007)
10.1111/j.1365-2710.1984.tb01088.x
THERAPEUTIC PROGRESS—REVIEW XIV
S. Nightingale (1984)
Evaluations on New Drugs
G. Totis (1979)
10.1111/j.1526-4610.2008.01202.x
Estrogen and Migraine: Correlations and Prevention
E. MacGregor (2008)
10.3109/02844319609072400
Effects of lipo-prostaglandin E1 on random pattern flaps in rabbits.
H. Kuwahara (1996)
10.1016/J.ARCPED.2004.10.012
Traitement médicamenteux de l'accès migraineux chez l'enfant
I.-C. Cuvellier (2005)
10.1046/j.1537-2995.1976.16376225504.x
Effect of Prostaglandin E‐1 Upon Microaggregate and Fibrin Formation in Stored Blood
J. Harp (1976)
Clinical Commwnkations: OWGYN
Jonathan Austin (1997)
10.1016/S0140-6736(04)16064-9
Migraine
S. Silberstein (2004)
10.1111/J.0954-6820.1983.TB03726.X
Migraine and the heart.
B. Johansson (1983)
10.1212/WNL.64.10_SUPPL_2.S9
Migraine as an inflammatory disorder
C. Waeber (2005)
10.1007/978-94-011-7843-3_8
Prostaglandins and their Synthesis Inhibitors in Migraine
J. Vardi (1979)
10.1016/0192-0561(83)90039-5
Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors.
J. Lieb (1983)
10.1007/S11916-004-0057-1
Menstrual migraine: A review of prophylactic therapies
V. Martin (2004)
10.1016/B978-0-433-07000-9.50007-4
CHAPTER II – General Pharmacology of Prostaglandins
J. Nakano (1972)
10.1016/S0003-4975(10)61799-7
Comparison of effects of prostaglandin E1 and nitroprusside on pulmonary vascular resistance in children after open-heart surgery.
L. Rubis (1981)
10.12968/PNUR.1996.7.17.5118
The role of female hormones
Anne MacGregor Mb (1996)
10.3390/ph3061966
NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data
Á. Párdutz (2010)
10.3810/PGM.1997.05.236
Menstrual migraine. Methods of prevention and control.
I. Fettes (1997)
10.1007/978-3-642-72466-4_5
Stellenwert der Prostanoid-Therapie, insbesondere von Prostaglandin E1, bei der Behandlung der peripheren arteriellen Verschlußkrankheit (PAVK) vom Oberschenkel- und Unterschenkeltyp bei Claudicatio intermittens und kritischer Ischämie
C. Diehm (1991)
10.1007/978-1-4899-3294-5
Drugs for Heart Disease
J. Hamer (1987)
10.1007/978-1-4615-9269-3_35
Prostaglandins in Cerebrospinal Fluid
R. P. White (1983)
10.1177/03331024860060S411
11: Naproxen Sodium in the Treatment of Migraine
K. Welch (1986)
10.1111/j.1365-2362.1986.tb02165.x
Effects of intra‐arterial prostaglandin E1 in patients with peripheral arterial occlusive disease
A. Creutzig (1986)
10.1007/978-1-4684-1173-7_4
Pathogenesis of Vascular Headaches
L. Kudrow (1983)
10.1001/JAMA.1978.03280490064032
Migraine. I. Classification and pathogenesis.
J. Saper (1978)
10.1016/S0031-6989(78)80100-3
Prostaglandin E1 increases basal glucagon in man.
D. Giugliano (1978)
Current Concepts of Cerebrovascular Disease — Stroke Clinical Applications of Prostaglandins and Their Inhibitors
Michael Ann Moskowitz (2011)
10.1007/978-3-642-88581-5_28
Controlled Trial of Diet in Migraine Patients
J. Egger (1985)
10.1046/J.1468-2982.1997.1701040.X
Ketoprofen and Carotico-Cavernous Fistula
E. A. Burton (1997)
See more
Semantic Scholar Logo Some data provided by SemanticScholar